RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced preliminary unaudited financial and operational results for the fourth quarter and fiscal year 2021.
Preliminary Unaudited Results
Preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $8.4 million, representing growth of approximately 71% compared to the prior year period, driven by:
Sale of 45 Light Delivery Devices (LDD™s), expanding the installed base to 206 LDDs as of December 31, 2021; and
Sale of 2,959 Light Adjustable Lenses (LAL®s).
Preliminary unaudited 2021 fiscal year revenue is expected to be approximately $22.6 million, representing growth of approximately 54% compared to the prior year, driven by:
Sale of 114 LDDs; and
Sale of 8,328 LALs.
Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2021, is expected to be approximately $159.3 million.
“Our fourth quarter financial results demonstrate continued adoption by innovative cataract surgeons and further acceptance by patients of the RxSight® value proposition for customized vision after cataract surgery,” said Ron Kurtz, CEO and President of RxSight. “With increasing awareness and availability of our LAL technology, the completed roll-out of ActivShield™, and our growing commercial team, we believe we are well positioned to drive continued growth in 2022.”
The Company’s fourth quarter and full year 2021 financial results are preliminary and are subject to the completion of the Company’s 2021 audit. Audited fourth quarter and full year 2021 financial results will be announced in early March.
https://finance.yahoo.com/news/rxsight-inc-announces-preliminary-unaudited-210000885.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.